Neuropeptide Y expression in primary cutaneous melanoma

J Eur Acad Dermatol Venereol. 2017 Mar;31(3):443-449. doi: 10.1111/jdv.13836. Epub 2016 Jul 18.

Abstract

Background: Neuropeptide Y (NPY) is involved in the carcinogenesis of different tumours, especially neural crest-derived tumours.

Objective: The aim of our study is to investigate the expression of NPY on melanoma and its relation with prognostic histological parameters and survival.

Methods: This is a retrospective observational study of two independent series, with a total of 79 primary melanomas, diagnosed in two independent University Hospitals in Spain, from January 2000 to December 2004.

Results: We found a significant higher expression of NPY on superficial spreading melanoma and lentigo maligna (40%) (P = 0.030). Thinner tumours were associated with higher NPY expression (Clark level, P = 0.003; Breslow level, P = 0.012). Melanomas with low NPY expression were associated with intense cell proliferation (Ki-67, P = 0.034), high density of peritumoral mast cell infiltrates (P = 0.033) and low E-cadherin expression (P = 0.031). Melanomas with high NPY expression exhibited significant differences in terms of relapse time (median: 114 vs. 68 months, P = 0.008) and overall survival (114 vs. 74 months, P = 0.004).

Conclusion: High expression of NPY was associated with better prognostic histological parameters, low peritumoral mast cells density, presence of adhesion proteins and better outcome.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cadherins / analysis
  • Cell Proliferation
  • Disease-Free Survival
  • Female
  • Humans
  • Hutchinson's Melanotic Freckle / chemistry
  • Hutchinson's Melanotic Freckle / pathology
  • Ki-67 Antigen / analysis
  • Male
  • Mast Cells
  • Melanoma / chemistry*
  • Melanoma / pathology
  • Middle Aged
  • Neuropeptide Y / analysis*
  • Retrospective Studies
  • Skin Neoplasms / chemistry*
  • Skin Neoplasms / pathology
  • Survival Rate
  • Tumor Burden

Substances

  • Cadherins
  • Ki-67 Antigen
  • Neuropeptide Y